为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
晚期或复发性肝细胞癌的免疫治疗
英文原题：Immunotherapy for advanced or recurrent hepatocellular carcinoma.
查看英文原题
Immunotherapy for advanced or recurrent hepatocellular carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肝细胞癌（HCC）具有高发病率和死亡率，并且由于肝脏的解剖和功能特征，容易发生肝内和肝外转移。由于根治性手术或射频消融相关的复杂性和高复发率，免疫检查点抑制剂（ICIs）越来越多地用于治疗HCC。几种免疫治疗药物及其联合方案已被临床批准用于治疗晚期或复发性HCC。本综述讨论了实践中主要的ICIs以及目前正在进行随机1-3期试验作为单药或联合治疗的ICIs。此外，我们总结了快速发展的替代策略，如嵌合抗原受体工程T细胞疗法和肿瘤疫苗。联合治疗是一种有前景的潜在治疗选择。本综述还对这些免疫疗法进行了总结，为未来建立可行且替代性的HCC治疗方法提供了关于优势、局限性和新角度的见解。
展开英文摘要原文
Hepatocellular carcinoma (HCC) is associated with high morbidity and mortality, and is prone to intra- and extrahepatic metastasis due to the anatomical and functional characteristics of the liver. Due to the complexity and high relapse rate associated with radical surgery or radiofrequency ablation, immune checkpoint inhibitors (ICIs) are increasingly being used to treat HCC.
Several immunotherapeutic agents, along with their combinations, have been clinically approved to treat advanced or recurrent HCC. This review discusses the leading ICIs in practice and those currently undergoing randomized phase 1-3 trials as monotherapy or combination therapy.
Furthermore, we summarize the rapidly developing alternative strategies such as chimeric antigen receptor-engineered T cell therapy and tumor vaccines. Combination therapy is a promising potential treatment option. These immunotherapies are also summarized in this review, which provides insights into the advantages, limitations, and novel angles for future research in establishing viable and alternative therapies against HCC.
论文信息
- 作者
- Luo YZ、Zhu H
- 第一作者单位
- Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.China
- 通讯作者单位
- Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. 441695131@qq.com.China
- 文献类型
- 综述
- 期刊
- World journal of gastrointestinal oncology2023 Mar 15
- 原文标识
- PubMed 37009314 · DOI 10.4251/wjgo.v15.i3.405
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →